BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...
Prostate cancer is the most common form of cancer among men in Western countries. Can aggressive prostate cancer eventually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results